AustraliaTuberculosis profile
Population  2015 24 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.044 (0.044–0.044) 0.18 (0.18–0.19)
Mortality (HIV+TB only) <0.01 (0–0.019) 0.02 (0–0.08)
Incidence  (includes HIV+TB) 1.4 (1.2–1.7) 6 (5.2–6.9)
Incidence (HIV+TB only) 0.029 (0.024–0.033) 0.12 (0.1–0.14)
Incidence (MDR/RR-TB)** 0.062 (0.039–0.085) 0.26 (0.16–0.35)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.05 (0.029–0.071) 0.64 (0.5–0.78) 0.69 (0.53–0.85)
Males 0.046 (0.03–0.062) 0.71 (0.55–0.86) 0.75 (0.58–0.92)
Total 0.096 (0.069–0.12) 1.3 (1.2–1.5) 1.4 (1.2–1.7)
TB case notifications, 2015  
Total cases notified 1 254
Total new and relapse 1 254
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 79%
          - % pulmonary 63%
          - % bacteriologically confirmed among pulmonary 88%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.03 (0.03–0.04)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 21 2%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  35
(23–48)
Estimated % of TB cases with MDR/RR-TB 3.6% (2.2–5.4) 24% (9.4–45)  
% notified tested for rifampicin resistance 76% 63% 961
MDR/RR-TB cases tested for resistance to second-line drugs   35
Laboratory-confirmed cases MDR/RR-TB: 37, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 35, XDR-TB: 2
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 79% 1 343
Previously treated cases, excluding relapse, registered in 2014 0% 13
HIV-positive TB cases, all types, registered in 2014 47% 17
MDR/RR-TB cases started on second-line treatment in 2013 86% 21
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data